Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiaSTAP in infants undergoing cardiopulmonary bypass
NCT02822599Phase 4Completed
- Sponsor
- Nicklaus Children's Hospital
- Start
- Jun 2017
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Fibrinogen human in hypofibrinogenemia, congenital afibrinogenemia and bleeding disorders, sponsored by Nicklaus Children's Hospital. Primary endpoints: Postoperative Blood Loss After Surgery (Estimated Blood Loss) at 24 hours and Post-operative Hemoglobin at 24 hours. Started Jun 2017; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
hypofibrinogenemiacongenital afibrinogenemiableeding disorders
Beyond the preview
Go deeper on NCT02822599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02822599.